Ben Hirschler reports:
Drugmakers are racing to scoop up patient health records and strike deals with technology companies as big data analytics start to unlock a trove of information about how medicines perform in the real world.
Studying such real-world evidence offers manufacturers a powerful tool to prove the value of their drugs – something Roche (ROG.S) aims to leverage, for example, with last month’s $2 billion purchase of Flatiron Health.
Read more on Reuters.